KBC Group
ELVN icon

KBC Group’s Enliven Therapeutics ELVN Stock Holding History

KBC Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38K Buy
+958
New +$26.5K ﹤0.01% 1738

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KBC Group's ELVN Position: Q1 2026 in Review

KBC Group opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 958 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #1738 among its holdings.

170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • KBC Group held 958 shares of Enliven Therapeutics worth $38K as of Q1 2026.
  • Enliven Therapeutics was a new KBC Group position in Q1 2026.
  • Enliven Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1738 holding.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.